Fig. 6: Immunogenicity and CMI responses elicited by mRNA VZV gE vaccine candidates in vivo. | npj Vaccines

Fig. 6: Immunogenicity and CMI responses elicited by mRNA VZV gE vaccine candidates in vivo.

From: A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses

Fig. 6

Female C57BL/6 mice were immunized with a full human dose of live attenuated VZV vaccine (Varivax®) to create preexisting immunity against VZV. Animals were subsequently immunized intramuscularly (IM) at day 35 and day 63 with 1 µg of our mRNA vaccine lead candidate LNP formulated material: gE WT_Co2 (frozen and lyophilized (Lyo) version), as well as frozen ms5_Co1 and ms6_Co2. Shingrix was also included and used as a positive control in the study. a Schematics of immunization and vaccination regimen schedule. Created in BioRender. Munoz-Moreno, R. (2024) https://BioRender.com/x92w358. b Blood was collected via submandibular route and gE-specific IgG antibodies (μg/ml) were measured by Luminex on day 76. c (%) of antigen induced specific CD4+ T cell responses from mice splenocytes were measured by intracellular cytokine staining (ICS) assay on day 76. Data is shown as the mean with standard deviation (SD). d (%) of antigen specific CD8+ T cell responses from mice splenocytes were measured by intracellular cytokine staining (ICS) assay on day 76. Data shows the median from 5 animals/group. Data is shown as the mean with SD.

Back to article page